


Ming-Yang He, Sheng-Chun  
Chen and Qun Chen\*Key Laboratory of Fine Petro-chemical  
Technology, Jiangsu Polytechnic University,  
Changzhou 213164, People's Republic of ChinaCorrespondence e-mail:  
chenqunjpu@yahoo.com

## Key indicators


Single-crystal X-ray study  
 $T = 298\text{ K}$   
Mean  $\sigma(\text{C}-\text{C}) = 0.003\text{ \AA}$   
 $R$  factor = 0.049  
 $wR$  factor = 0.126  
Data-to-parameter ratio = 16.3For details of how these key indicators were  
automatically derived from the article, see  
<http://journals.iucr.org/e>.*N,N'*-[(2,3,5,6-Tetrafluoro-1,4-phenylene)-  
dimethylene]bis(pyridine-4-carboxamide)In the centrosymmetric molecule of the title compound,  $\text{C}_{20}\text{H}_{14}\text{F}_4\text{N}_4\text{O}_2$ , the pyridine ring is twisted with respect to the benzene ring with a dihedral angle of  $66.85(10)^\circ$ . In the crystal structure, molecules are linked by intermolecular hydrogen-bonding and  $\text{C}-\text{H}\cdots\pi$  interactions.Received 27 July 2006  
Accepted 3 August 2006

## Comment


Pyridinecarboxamide derivatives have attracted much attention because of their biological activity. Some derivatives of pyridinecarboxamide possess anticancer (Liu *et al.*, 1996) and anti-allergic activities (Tsurahara *et al.*, 1987), and are efficient as IKK inhibitors (Li & Prakash, 2005), monoamine oxidase B inhibitors (Blauenstein *et al.*, 1998) and anti-convulsant drugs (Palmer *et al.*, 1993). As part of a search for new pyridinecarboxamide compounds with better biological activity, the title compound, (I), has been synthesized. Here we report the crystal structure.The molecular structure of (I) is shown in Fig. 1. The molecule of (I) is centrosymmetric. The pyridine ring is twisted with respect to the benzene ring, with a dihedral angle of  $66.85(10)^\circ$ .Weak  $\text{C}-\text{H}\cdots\pi$  interactions are observed in the crystal structure (Fig. 2);  $\text{C3}-\text{H3} = 0.93$ ,  $\text{H3}\cdots\text{Cg}^{\text{iv}} = 2.97$ ,  $\text{C3}\cdots\text{Cg}^{\text{iv}} = 3.726(3)\text{ \AA}$  and  $\text{C3}-\text{H3}\cdots\text{Cg}^{\text{iv}} = 139^\circ$ ;  $\text{C5}-\text{H5} = 0.93$ ,  $\text{H5}\cdots\text{Cg}^{\text{v}} = 3.05$ ,  $\text{C5}\cdots\text{Cg}^{\text{v}} = 3.756(3)\text{ \AA}$  and  $\text{C5}-\text{H5}\cdots\text{Cg}^{\text{v}} = 133^\circ$  [Cg is the centroid of the pyridine ring; symmetry codes: (iv)  $\frac{5}{2} - x, \frac{1}{2} + y, \frac{3}{2} - z$ ; (v)  $\frac{3}{2} - x, -\frac{1}{2} + y, \frac{3}{2} - z$ ]. Classical  $\text{N}-\text{H}\cdots\text{O}$  and weak  $\text{C}-\text{H}\cdots\text{O}$  and  $\text{C}-\text{H}\cdots\text{F}$  hydrogen bonding occurs in the crystal structure (Table 1), which helps to stabilize the crystal structure (Fig. 3).

## Experimental


To a stirred suspension of isonicotiny chloride (3.92 g, 22 mmol) and 1,4-bis(aminomethyl)-2,3,5,6-tetrafluorobenzene (2.08 g, 10 mmol) in dry tetrahydrofuran (25 ml) was added dropwise triethylamine (3 ml) at 273 K. The mixture was maintained at room temperature for 48 h

**Figure 1**

The molecular structure of (I), drawn with 30% probability ellipsoids (arbitrary spheres for H atoms) [symmetry code: (A)  $1 - x, 1 - y, 2 - z$ ].

**Figure 2**

The C—H... $\pi$  interactions (dashed lines) in (I).

**Figure 3**

A packing diagram for (I). Dashed lines indicate hydrogen bonds.

with stirring under a nitrogen atmosphere, then evaporated to dryness. The resulting residue was washed with iced water (25 ml), saturated sodium carbonate solution (12 ml), and again with iced water (15 ml). After work-up, the crude product was dried under vacuum and purified by recrystallization from methanol to yield (I) (3.81 g, 91% yield) as a white solid. Single crystals of (I) were obtained by slow evaporation of a methanol solution.

**Crystal data**

$C_{20}H_{14}F_4N_4O_2$	$Z = 2$
$M_r = 418.35$	$D_x = 1.567 \text{ Mg m}^{-3}$
Monoclinic, $P2_1/n$	Mo $K\alpha$ radiation
$a = 8.3488 (17) \text{ \AA}$	$\mu = 0.13 \text{ mm}^{-1}$
$b = 5.1431 (11) \text{ \AA}$	$T = 298 (2) \text{ K}$
$c = 20.665 (4) \text{ \AA}$	Block, colorless
$\beta = 91.843 (2)^\circ$	$0.30 \times 0.20 \times 0.13 \text{ mm}$
$V = 886.9 (3) \text{ \AA}^3$	

**Data collection**

Bruker SMART APEX CCD area-detector diffractometer	2213 independent reflections
$\varphi$ and $\omega$ scans	1302 reflections with $I > 2\sigma(I)$
Absorption correction: none	$R_{\text{int}} = 0.044$
7535 measured reflections	$\theta_{\text{max}} = 28.5^\circ$

**Refinement**

Refinement on $F^2$	$w = 1/[\sigma^2(F_o^2) + (0.0524P)^2 + 0.1461P]$
$R[F^2 > 2\sigma(F^2)] = 0.049$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.126$	$(\Delta/\sigma)_{\text{max}} < 0.001$
$S = 1.03$	$\Delta\rho_{\text{max}} = 0.18 \text{ e \AA}^{-3}$
2213 reflections	$\Delta\rho_{\text{min}} = -0.21 \text{ e \AA}^{-3}$
136 parameters	
H-atom parameters constrained	

**Table 1**

Hydrogen-bond geometry ( $\text{\AA}, ^\circ$ ).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$N2-H2A\cdots O1^i$	0.88	2.10	2.927 (2)	155
$C4-H4\cdots F2^{ii}$	0.93	2.53	3.242 (3)	134
$C7-H7B\cdots O1^{iii}$	0.97	2.50	3.393 (3)	153

Symmetry codes: (i)  $x, y - 1, z$ ; (ii)  $x + \frac{1}{2}, -y + \frac{1}{2}, z - \frac{1}{2}$ ; (iii)  $-x + 2, -y + 2, -z + 2$ .

The imino H atoms were located in a difference Fourier map and refined as riding in their as-found relative positions, with  $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{N})$ . Other H atoms were placed in calculated positions, with  $C-H = 0.97$  (methylene) or  $0.93 \text{ \AA}$  (aromatic), and refined in riding mode, with  $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$ .

Data collection: *SMART* (Bruker, 2000); cell refinement: *SAINT* (Bruker, 2000); data reduction: *SAINT*; program(s) used to solve structure: *SHELXTL* (Bruker, 2000); program(s) used to refine structure: *SHELXTL*; molecular graphics: *SHELXTL*; software used to prepare material for publication: *SHELXTL*.

**References**

- Blauenstein, P., Remy, N., Buck, A., Ametamey, S., Haberli, M. & Schubiger, P. A. (1998). *Nucl. Med. Biol.* **25**, 47–52.
- Bruker (2000). *SMART, SAINT and SHELXTL*. Bruker AXS Inc., Madison, Wisconsin, USA.
- Li, Y. & Prakash, S. R. (2005). *J. Label. Compd Radiopharm.* **48**, 323–330.
- Liu, Q., Zhang, S.-W., Wei, Y. G. & Shao, M.-C. (1996). *Acta Cryst.* **C52**, 2260–2261.
- Palmer, R. A., Puddle, N. & Lisgarten, J. N. (1993). *Acta Cryst.* **C49**, 1777–1779.
- Tsuzurahara, K., Ishikawa, S., Ono, Y., Murata, T., Kikuchi, M. & Takeyama, S. (1987). *Jpn J. Phar.* **45**, 55–62.